6 completed, 4 terminated, 2 active not recruiting, 1 recruiting. 14 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 6, Terminated 4, Active not recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
Follow Camurati-Engelmann Syndrome: new trials by email Literature Review of Camurati-Engelmann Syndrome trials Research Report on Camurati-Engelmann Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors HCB301 - Advanced Solid Tumor, Refractory Hodgkin Lymphoma | Phase 1 | Recruiting | FBD Biologics Limited | 50 | 2025-04-02 | 2026-04-13 |
| Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial Metformin Hydrochloride, betamethasone dipropionate, Pentoxifylline - Oral Submucous Fibrosis | Phase 1 / Phase 2 | Completed | Ziauddin University | 30 | 2024-08-12 | 2025-05-02 |
| Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors TST005 - Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm | Phase 1 | Terminated | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 19 | 2021-06-11 | 2023-10-23 |
| Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) M7824, Carboplatin, Paclitaxel - Cervical Cancer | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 25 | 2020-10-19 | 2024-03-08 |
| Losartan to Improve Hip Microfracture Losartan, Placebo - Hip Osteoarthritis, Hip Impingement Syndrome | Phase 1 / Phase 2 | Terminated | Steadman Philippon Research Institute | 1 | 2020-08-07 | 2023-10-30 |
| Bioimaging Study of 89Zr-M7824 in NSCLC 89Zirconium-M7824, M7824 - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Olivia Newton-John Cancer Research Institute | 5 | 2020-06-01 | 2023-01-17 |
| A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer LY3200882, Pembrolizumab - Advanced Cancer | Phase 1 / Phase 2 | Withdrawn | Eli Lilly and Company | 2019-12-05 | 2020-02-19 | |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors PF-06952229, Enzalutamide - Breast Neoplasms, Prostate Neoplasms | Phase 1 | Terminated | Pfizer | 49 | 2018-10-04 | 2024-06-26 |
| A Study of LY3200882 in Participants With Solid Tumors LY3200882, LY3300054, Gemcitabine - Solid Tumor | Phase 1 | Active not recruiting | Eli Lilly and Company | 223 | 2016-11-21 | 2026-04-03 |
| TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC DNR.NPC-specific T cells, DNR.NPC-specific T cells + cyclophosphamide + fludarabine - EBV-positive Nasopharyngeal Carcinoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 14 | 2015-02-01 | 2026-01-29 |
| First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors TEW-7197 - Advanced Stage Solid Tumors | Phase 1 | Completed | MedPacto, Inc. | 35 | 2014-07-29 | 2019-05-09 |
| Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy TGFBeta resistant HER2/EBV-CTLs - HER2 Positive Malignancies | Phase 1 | Completed | Baylor College of Medicine | 20 | 2009-05-01 | 2018-09-18 |
| Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals Sitagliptin (Januvia) - Diabetes Mellitus Type 1, Diabetes Mellitus Type 2 | Phase 1 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 76 | 2009-01-06 | 2019-11-29 |
| A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer fenretinide - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 75 | 1994-01-01 | 2008-03-04 |
Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Fibrosis (1) · Hodgkin Disease (1) · Keratoacanthoma familial (1)
Bone Diseases (14) · Bone Diseases, Developmental (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Genetic Diseases, Inborn (14) · Musculoskeletal Diseases (14) · Osteochondrodysplasias (14) · Neoplasms (6) · Neoplasms by Site (6) · Neoplasms by Histologic Type (4) · Carcinoma (3) · Neoplasms, Glandular and Epithelial (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Breast Diseases (2) · Bronchial Neoplasms (2)
Cisplatin (2) · bintrafusp alfa protein, human (2) · 130-nm albumin-bound paclitaxel (1) · Betamethasone Valerate (1) · Bevacizumab (1) · Carboplatin (1) · Cyclophosphamide (1) · Fenretinide (1) · Gemcitabine (1) · LY3300054 (1) · Losartan (1) · Metformin (1) · Paclitaxel (1) · Pentoxifylline (1) · Radiotherapy (1)
Baylor College of Medicine (2) · Eli Lilly and Company (2) · EMD Serono Research & Development Institute, Inc. (1) · FBD Biologics Limited (1) · MedPacto, Inc. (1) · National Cancer Institute (NCI) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Olivia Newton-John Cancer Research Institute (1) · Pfizer (1) · Steadman Philippon Research Institute (1) · Transcenta Therapeutics (Hangzhou) Co., Ltd. (1) · Ziauddin University (1)
United States (12) · Spain (3) · Australia (2) · France (2) · Japan (2) · Canada (1) · China (1) · Germany (1) · Italy (1) · Pakistan (1) · Taiwan (1)
Andrew M Scott, MBBS (1) · Charlie Qi, MD (1) · Helen Heslop, MD (1) · Hui K Gan, MBBS (1) · Ilho Ha, PhD (1) · Kristina I Rother, M.D. (1) · Marc J Philippon, MD (1) · Stepehen Gottschalk, MD (1)
PMID 28390753, PMID 31472446, PMID 33008091, PMID 34007848, PMID 34548321, PMID 35410255, PMID 36552855, PMID 39214047
2016 (1), 2019 (1), P01CA094237 (1)